Acetate Supplementation May Reduce Psychotropic-Induced Weight Gain and Dyslipidemia

The clinical management of affective disorders is frequently complicated by the metabolic burden of psychotropic medications, which often trigger significant weight gain and dyslipidemia [1, 2]. These systemic changes are increasingly linked to the microbiota-gut-brain axis, a complex bidirectional communication network involving microbial metabolites and the central nervous system [3, 4]. Short-chain fatty acids, which are metabolic byproducts of bacterial fermentation such as acetate and butyrate, serve as critical signaling molecules within this axis, influencing both intestinal homeostasis and neuro-immunoendocrine function [5, 4]. While the clinical impact of gut dysbiosis (a pathological imbalance in microbial communities) is well-documented in metabolic and psychiatric conditions, therapeutic strategies to restore this balance remain a focus of active investigation [6, 7]. A recent case-series involving 11 participants aged 22 to 32 evaluated the use of delayed-release acetate capsules to mitigate medication-related weight gain [1]. The study found that six participants demonstrated metabolic improvements, including clinically meaningful changes in cholesterol and weight, while genetic sequencing of the gut microbiome revealed an increased relative abundance of butyrate-producing bacteria [1].